Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

PURPOSE: Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and VEGF receptor kinases in PTC. PATIENTS AND METHODS: The primary end point was the obj...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kloos, Richard T., Ringel, Matthew D., Knopp, Michael V., Hall, Nathan C., King, Mark, Stevens, Robert, Liang, Jiachao, Wakely, Paul E., Vasko, Vasyl V., Saji, Motoyasu, Rittenberry, Jennifer, Wei, Lai, Arbogast, Daria, Collamore, Minden, Wright, John J., Grever, Michael, Shah, Manisha H.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2009
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668972/
https://ncbi.nlm.nih.gov/pubmed/19255327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.18.2717
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires